Results 1 to 10 of about 364,790 (104)

Booster Vaccination With GVGH Shigella sonnei 1790GAHB GMMA Vaccine Compared to Single Vaccination in Unvaccinated Healthy European Adults: Results From a Phase 1 Clinical Trial [PDF]

Frontiers in Immunology, 2019
The investigational Shigella sonnei vaccine (1790GAHB) based on GMMA (generalized modules for membrane antigens) is immunogenic, with an acceptable safety profile in adults. However, pre-vaccination anti-S. sonnei lipopolysaccharide (LPS) antibody levels
Odile Launay, Odile Launay, Odile Launay, Augustin G. W. Ndiaye, Valentino Conti, Pierre Loulergue, Pierre Loulergue, Pierre Loulergue, Antonella Silvia Sciré, Anais Maugard Landre, Anais Maugard Landre, Anais Maugard Landre, Pietro Ferruzzi, Naouel Nedjaai, Naouel Nedjaai, Naouel Nedjaai, Lena Dorothee Schütte, Joachim Auerbach, Elisa Marchetti, Allan Saul, Laura B. Martin, Audino Podda   +21 more
doaj   +11 more sources

A Phase 2a Randomized Study to Evaluate the Safety and Immunogenicity of the 1790GAHB Generalized Modules for Membrane Antigen Vaccine against Shigella sonnei Administered Intramuscularly to Adults from a Shigellosis-Endemic Country [PDF]

Frontiers in Immunology, 2017
Shigellosis is a mild-to-severe diarrheal infection, caused by the genus Shigella, and is responsible for significant morbidity and mortality worldwide.
Christina W. Obiero, Augustin G. W. Ndiaye, Antonella Silvia Sciré, Bonface M. Kaunyangi, Elisa Marchetti, Ann M. Gone, Lena Dorothee Schütte, Daniele Riccucci, Joachim Auerbach, Allan Saul, Laura B. Martin, Philip Bejon, Patricia Njuguna, Patricia Njuguna, Audino Podda   +14 more
doaj   +9 more sources

Efficacy, safety, and immunogenicity of the Shigella sonnei 1790GAHB GMMA candidate vaccine: Results from a phase 2b randomized, placebo-controlled challenge study in adults [PDF]

EClinicalMedicine, 2021
Background: Shigellosis accounts for substantial morbidity and mortality worldwide and is the second most common cause of moderate and severe diarrhoea in children.
Robert W. Frenck, Jr, Valentino Conti, Pietro Ferruzzi, Augustin G.W. Ndiaye, Susan Parker, Monica Malone McNeal, Michelle Dickey, Juan Paolo Granada, Giulia Luna Cilio, Iris De Ryck, Francesca Necchi, Akamol E. Suvarnapunya, Omar Rossi, Alessandra Acquaviva, Lakshmi Chandrasekaran, Kristen A. Clarkson, Joachim Auerbach, Elisa Marchetti, Robert W. Kaminski, Francesca Micoli, Rino Rappuoli, Allan Saul, Laura B. Martin, Audino Podda   +23 more
doaj   +7 more sources

Antibodies Elicited by the Shigella sonnei GMMA Vaccine in Adults Trigger Complement-Mediated Serum Bactericidal Activity: Results From a Phase 1 Dose Escalation Trial Followed by a Booster Extension [PDF]

Frontiers in Immunology, 2021
Shigella is the second most deadly diarrheal disease among children under five years of age, after rotavirus, with high morbidity and mortality in developing countries.
Francesca Micoli, Omar Rossi, Valentino Conti, Odile Launay, Odile Launay, Antonella Silvia Sciré, Maria Grazia Aruta, Usman Nasir Nakakana, Elisa Marchetti, Rino Rappuoli, Allan Saul, Laura B. Martin, Francesca Necchi, Audino Podda   +13 more
doaj   +5 more sources

Putative correlates of protection against shigellosis assessing immunomarkers across responses to S. sonnei investigational vaccine [PDF]

npj Vaccines
Shigella spp. are a leading bacterial cause of diarrhea. No widely licensed vaccines are available and there is no generally accepted correlate of protection. We tested a S.
Valentino Conti, Omar Rossi, Kristen A. Clarkson, Francesca Mancini, Usman N. Nakakana, Eleanna Sarakinou, Andrea Callegaro, Pietro Ferruzzi, Alessandra Acquaviva, Ashwani Kumar Arora, Elisa Marchetti, Francesca Necchi, Robert W. Frenck, Laura B. Martin, Robert W. Kaminski, Audino Podda, Francesca Micoli   +16 more
doaj   +4 more sources

Protein-specific immune response elicited by the Shigella sonnei 1790GAHB GMMA-based candidate vaccine in adults with varying exposure to Shigella [PDF]

mSphere
Shigella is a leading cause of diarrheal morbidity and mortality in young children from low- and middle-income countries. Here, we aimed to verify the ability of the generalized modules for membrane antigens (GMMA)-based Shigella sonnei candidate vaccine
Arlo Z. Randall, Valentino Conti, Usman Nakakana, Xiaowu Liang, Andy A. Teng, Antonio Lorenzo Di Pasquale, Melissa Kapulu, Robert Frenck, Odile Launay, Pietro Ferruzzi, Antonella Silvia Sciré, Elisa Marchetti, Christina Obiero, Jozelyn V. Pablo, Joshua Edgar, Philip Bejon, Adam D. Shandling, Joseph J. Campo, Angela Yee, Laura B. Martin, Audino Podda, Francesca Micoli   +21 more
doaj   +7 more sources

Production of a Shigella sonnei Vaccine Based on Generalized Modules for Membrane Antigens (GMMA), 1790GAHB. [PDF]

PLoS ONE, 2015
Recently, we developed a high yield production process for outer membrane particles from genetically modified bacteria, called Generalized Modules of Membrane Antigens (GMMA), and the corresponding simple two step filtration purification, enabling ...
Christiane Gerke, Anna Maria Colucci, Carlo Giannelli, Silvia Sanzone, Claudia Giorgina Vitali, Luigi Sollai, Omar Rossi, Laura B Martin, Jochen Auerbach, Vito Di Cioccio, Allan Saul   +10 more
doaj   +7 more sources

Complement-mediated serum bactericidal activity of antibodies elicited by the Shigella sonnei GMMA vaccine in adults from a shigellosis-endemic country: Exploratory analysis of a Phase 2a randomized study [PDF]

Frontiers in Immunology, 2022
Shigella is associated with a significant burden of disease worldwide among individuals of all ages and is the major cause of moderate and severe diarrhea in children under five years of age in low- and middle-income countries. Several candidate vaccines
Melissa C. Kapulu, Melissa C. Kapulu, Usman Nakakana, Antonella S. Sciré, Eleanna Sarakinou, Valentino Conti, Omar Rossi, Alessandra Acquaviva, Francesca Necchi, Christina W. Obiero, Laura B. Martin, Philip Bejon, Philip Bejon, Patricia Njuguna, Francesca Micoli, Audino Podda   +15 more
doaj   +2 more sources

Testing S. sonnei GMMA with and without Aluminium Salt-Based Adjuvants in Animal Models [PDF]

Pharmaceutics
Shigellosis is one of the leading causes of diarrheal disease in low- and middle-income countries, particularly in young children, and is more often associated with antimicrobial resistance.
Francesca Mancini, Valentina Caradonna, Renzo Alfini, Maria Grazia Aruta, Claudia Giorgina Vitali, Gianmarco Gasperini, Diego Piccioli, Francesco Berlanda Scorza, Omar Rossi, Francesca Micoli   +9 more
doaj   +2 more sources

Safety Profile and Immunologic Responses of a Novel Vaccine Against Shigella sonnei Administered Intramuscularly, Intradermally and Intranasally: Results From Two Parallel Randomized Phase 1 Clinical Studies in Healthy Adult Volunteers in Europe [PDF]

EBioMedicine, 2017
Background: Approximately 164,000 deaths yearly are due to shigellosis, primarily in developing countries. Thus, a safe and affordable Shigella vaccine is an important public health priority.
Odile Launay, David J.M. Lewis, Alessandra Anemona, Pierre Loulergue, Jo Leahy, Antonella Silvia Sciré, Anaïs Maugard, Elisa Marchetti, Stefano Zancan, Zhiming Huo, Simona Rondini, Rachid Marhaba, Oretta Finco, Laura B. Martin, Jochen Auerbach, Daniel Cohen, Allan Saul, Christiane Gerke, Audino Podda   +18 more
doaj   +2 more sources